Doctors who reported how men with cancer treatment that starts from spreading through the prostate to mention that the chance of living increased significantly if the radiation were added with hormone treatment.
Studies on the prostate has potentially changed the way of treatment. Approximately 20% of the 200 thousand men are diagnosed with this disease in the U.S., where the cancer has spread to areas around the prostate.
"It is a patient group in which many deaths from prostate cancer patients because this condition is usually not curable," said study chief Dr. Padraig Warde, radiation experts from the Princess Margaret Hospital, University of Toronto.
This study followed 1200 men who received hormone therapy and radiation and hormone therapy in itself. After seven years, 74% of men who received both treatments was kept alive compared with 66% who only get hormone therapy.
"This conclusion shows that radiation is an indispensable element in the treatment of patients with high risk prostate cancer," said Dr. Jennifer Obel, cancer specialist at Northshore University Health System in the district of Chicago.
"This is a study of change in practice in some countries, especially in Europe, where more men didiganosa with tumors than in the U.S.," said Obel.
In the U.S., sektiar 192 280 new cases of prostate cancer has been diagnosed years ago and mentioned that only 27 360 who managed to live.
On the other hand, the breast cancer study was also conducted. This study uses eribulin, drugs derived from sea coral. Unlike Herceptin or other drugs that are the focus in cancer research in a few decades earlier. This treatment is associated with chemotherapy, how to kill cells by attacking kaker new cell division.
This study was conducted on 762 women who have cancer after initial treatment, or it has spread in their breasts. Everything got worse after an average of four tries to a recommended drug. Two-thirds of drugs and other eribulin accept whatever doctor they want, considering there is no standard treatment in this situation.
About half of women who try eribulin feel similar effects with chemotherapy. Fatigue, white blood cell count declines, the thinning hair, nd tingling numbness in several different parts of the body. Approximately one-fourth of women in other groups experienced serious impacts associated with their treatment.
"Not many drugs that show an ability to stay alive in this act, but the number of studies that use the profits from this eribulin be 'reasonable way' that can be used," said Dr. Eric Winer, chief of breast cancer at the Dana-Farber Cancer Institute, Boston.
More than one million women around the world have been diagnosed with breast cancer each year. In the United States last year, has estimated there are 194 280 new cases and as many as 40 610 deaths from this disease.
0 comments:
Post a Comment